More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Mesoblast (NASDAQ:MESO – Get Free Report) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Monday, MarketBeat ...

Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Jefferies downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company’s for the ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Mesoblast ( (MESO) ) has shared an update.

FDA approval for Mesoblast’s cell therapy used to treat children for complications that can occur during bone marrow ...

It’s clear that the biotech sector’s potential is far from being fully realized, especially when companies like Mesoblast are breaking new ground. Mesoblast is not just another biotech company; it is ...

Investors are sending the Mesoblast share price tumbling on Friday. But why? The post Why the Mesoblast share price is diving ...

Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...

Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...